Efficacy and safety of neoadjuvant therapy with tislelizumab plus axitinib for nonmetastatic renal cell carcinoma with inferior vena cava tumor thrombus: a retrospective study

Abstract In renal cell carcinoma (RCC) patients with inferior vena cava (IVC) tumor thrombus, neoadjuvant therapy could alleviate the burden of tumor thrombus, enhance the safety and feasibility of surgical resection, and improve patient prognosis. The combination of tislelizumab and axitinib has de...

Volledige beschrijving

Bibliografische gegevens

Hoofdauteurs:	Zhongjie Zhao, Zhengsheng Liu, Kaiyan Zhang, Wei Li, Lijian Zhang, Bingliang Jiang, Bin Chen, Jinchun Xing, Xuegang Wang
Formaat:	Artigo
Taal:	Inglês
Gepubliceerd in:	Nature Portfolio 2025-01-01
Reeks:	Scientific Reports
Onderwerpen:	Tislelizumab Axitinib Renal cell carcinoma (RCC) Inferior vena cava (IVC) tumor thrombus Neoadjuvant therapy
Online toegang:	https://doi.org/10.1038/s41598-025-86712-6
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!